TMO
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc historical holders
total: 22
Weitz Value Fund Thermo Fisher Scientific Inc transactions over time
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 4
- Reduced:
- 7
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
Wallace Weitz has been an institutional investor in Thermo Fisher Scientific Inc (TMO) since 2019 Q3. According to 2026 Q1 report, Wallace Weitz holds 76,250 shares with a market value of roughly $37.48M representing 5.96% of their equity portfolio. The fund/company first acquired TMO in 2019 Q3, initially purchasing 100,000 shares. Since the initial investment, Weitz Value Fund has made 11 more transactions in this position.
Does Wallace Weitz still hold TMO?
Yes, Wallace Weitz continues to hold Thermo Fisher Scientific Inc (TMO). According to their 2026 Q1 report, they maintain a position of 76,250 shares valued at approximately $37.48M, representing 5.96% of their equity portfolio.
When did Wallace Weitz first invest in TMO?
Wallace Weitz first invested in Thermo Fisher Scientific Inc (TMO) in 2019 Q3 at the reported quarter-end price of $291.27 per share, acquiring 100,000 shares in their initial purchase.
What is Wallace Weitz's average cost basis for TMO?
Based on historical transaction data, Wallace Weitz's estimated cost basis for Thermo Fisher Scientific Inc (TMO) is approximately $330.63 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $330.62
- Weighted AVG sell price:
- $500.04
TMO transactions history by Weitz Value Fund
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
5.96%
|
76,250
|
$491.53
|
$37,479,162
|
-10.29% (-8,750)
|
-0.57%
|
|
2025 Q4
|
6.49%
|
85,000
|
$579.45
|
$49,253,250
|
-3.41% (-3,000)
|
-0.21%
|
|
2025 Q2
|
4.19%
|
88,000
|
$405.46
|
$35,680,480
|
+17.33% (+13,000)
|
+0.62%
|
|
2023 Q3
|
4.54%
|
75,000
|
$506.17
|
$37,962,750
|
+15.38% (+10,000)
|
+0.61%
|
|
2023 Q2
|
3.98%
|
65,000
|
$521.75
|
$33,913,750
|
+8.33% (+5,000)
|
+0.31%
|
|
2022 Q4
|
4.45%
|
60,000
|
$550.69
|
$33,041,400
|
-7.69% (-5,000)
|
-0.39%
|
|
2022 Q3
|
4.62%
|
65,000
|
$507.19
|
$32,967,350
|
-7.14% (-5,000)
|
-0.33%
|
|
2021 Q4
|
4.48%
|
70,000
|
$667.24
|
$46,706,800
|
-6.67% (-5,000)
|
-0.33%
|
|
2021 Q1
|
3.69%
|
75,000
|
$456.38
|
$34,228,500
|
+2.74% (+2,000)
|
+0.1%
|
|
2020 Q4
|
3.88%
|
$465.78
|
-14.12% (-12,000)
|
|||
|
2020 Q3
|
4.62%
|
$441.52
|
-15.00% (-15,000)
|
|||
|
2019 Q3
|
3.56%
|
$291.27
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.